Please login to the form below

Not currently logged in
Email:
Password:

epilepsy

This page shows the latest epilepsy news and features for those working in and with pharma, biotech and healthcare.

Medicinal cannabis firm Althea enters UK market

Medicinal cannabis firm Althea enters UK market

That includes children with rare, severe forms of epilepsy, adults with vomiting or nausea caused by chemotherapy, and adults with muscle symptoms caused by multiple sclerosis. ... and young people with epilepsy, which will be a prelude to formal NICE

Latest news

  • Afinitor and Uptravi gain funding from NHS England Afinitor and Uptravi gain funding from NHS England

    Rare disease treatments navigate tricky market access route. Novartis’ Afinitor in Tuberous Sclerosis Complex (TSC)-related epilepsy patients and Actelion’s pulmonary arterial hypertension (PAH) treatment Uptravi (selexipag) have gained funding

  • Orphan drugs dominate FDA's record-breaking year Orphan drugs dominate FDA's record-breaking year

    in the body where the tumour originated (after Merck &Co’s Keytruda), and GW Pharma’s epilepsy therapy Epidiolex (cannabidiol) which is the first FDA-approved drug based on cannabis.

  • The Final Frontier The Final Frontier

    But let’s talk about gabapentin. In Canada and the US, gabapentin is indicated as an adjunctive therapy for patients with epilepsy, who are not adequately controlled with conventional therapy.

  • Medical cannabis now available on prescription, for some Medical cannabis now available on prescription, for some

    GPs won’t be able to prescribe these products, and new NHS guidance for England says that they should only be made available to children with rare, severe forms of epilepsy, ... Home Secretary Sajid Javid announced the initiative in the summer, in the

  • Teva wins FDA OK for crucial migraine drug Teva wins FDA OK for crucial migraine drug

    other preventive options such as Botox and anti-epilepsy drugs like topiramate because their long-tern safety is still unclear.

More from news
Approximately 25 fully matching, plus 168 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    The oral solution treats seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older, two of the most difficult-to-treat epilepsy-related ... a strong epilepsy or specialist disease experience.

  • A quest for innovative solutions A quest for innovative solutions

    new ways of monitoring major depressive order, epilepsy and multiple sclerosis using wearable devices and smartphone technology. ... Take epilepsy, for instance, where 20% of patients are being misdiagnosed, which is substantial.

  • A healthcare landscape going through seismic change A healthcare landscape going through seismic change

    The company is still reeling from its record £84.2m fine last December from the UK government’s Competition and Markets Authority for allegedly charging excessive prices for its anti-epilepsy

  • Tackling the challenge of non-adherence Tackling the challenge of non-adherence

    In earlier research, the likelihood of dying prematurely for patients with epilepsy who did not take their medicines was threefold that of patients who did.

  • Deal Watch January 2017 Deal Watch January 2017

    of rare paediatric epilepsies.

More from intelligence
Approximately 1 fully matching, plus 9 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

The importance of co-creation with patients
Overcoming the barriers...
Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics